Thank you, Mr. Chair.
I'd like to welcome all the witnesses to the Standing Committee on Health.
In 2016, this committee tabled a report in the House of Commons that included 38 recommendations. One of these recommendations said that the Canadian drugs and substances strategy should be focused on reducing harm and that the government should define what harm reduction means.
Seven years on, could you briefly tell us what harm reduction consists of and what its goals are?